RxDoctor Payments Data

Natalie Borg, DO

Family Medicine · Bradenton, FLNPI 1841447364

Payments from drug & device makers

$1,609in general payments, 2019–2025

Across 84 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$435
  • Novo Nordisk$412
  • Pfizer$212
  • GSK$155
  • Exact Sciences$141
  • Amgen$85
  • plus $169 from 8 others

What the payments were for

  • Food & beverage$1,609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)21$435
Novo Nordisk22$412
Pfizer10$212
GSK9$155
Exact Sciences6$141
Amgen(2 entities)5$85
Johnson & Johnson4$49
Boston Scientific1$22
Astellas Pharma US Inc1$20
Abbott1$19
Lilly USA, LLC1$17
Boehringer Ingelheim1$15
AstraZeneca1$14
Novartis1$13

How this compares

$1,609 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$197,784
Medicare patients
315
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab41$59,657
EliquisApixaban48$58,365
MounjaroTirzepatide16$31,593
OzempicSemaglutide18$30,219
JardianceEmpagliflozin22$29,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,741
FarxigaDapagliflozin Propanediol18$22,539
XareltoRivaroxaban14$21,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$19,031
JanuviaSitagliptin Phosphate17$15,225
Dexlansoprazole DrDexlansoprazole14$4,930
Rosuvastatin Calcium344$3,919
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,425
SynthroidLevothyroxine Sodium47$3,127
Pravastatin Sodium185$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$212$58,36548 claims
AstraZenecaFarxiga, Breztri Aerosphere$14$41,57045 claims
Lilly USA, LLCMounjaro$17$31,59316 claims
Novo NordiskOzempic$412$30,21918 claims
Boehringer IngelheimJardiance$15$29,45722 claims
GSKTrelegy Ellipta$155$24,74129 claims
Johnson & JohnsonXarelto$49$21,57714 claims
AbbVieSynthroid$435$3,12747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →